Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
A second immunotherapy option is now available for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.